The uptake and release of the natural polyamines putrescine, spermidine and spermine by
mammalian cells are integral parts of the systems that regulate the intracellular …

Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine
subspecialty. For many decades, treatment with radionuclides has been mainly restricted to …

Sigma receptors are classified into sigma1 and sigma2 subtypes. These subtypes display a
different tissue distribution and a distinct physiological and pharmacological profile in the …

Sigma receptors (subtypes sigma-1 and sigma-2) are a unique class of binding sites
expressed throughout the mammalian body. The endogenous ligand for these sites has not …

Cutaneous melanoma arises from proliferating melanocytes, cells specialized in the
production of melanin. This property means melanin can be considered as a target for …

Targeted radionuclide therapy using radioiodinated compounds with a specific affinity for
melanoma tissue is a promising treatment for disseminated melanoma, but the candidate …

Nearly 100,000 individuals are expected to be diagnosed with melanoma in the United
States in 2022. Treatment options for late-stage metastatic disease up until the 2010s were …

Melanoma represents the most aggressive form of skin cancer, and its incidence continues
to rise worldwide. 18 F–FDG PET imaging has transformed diagnostic nuclear medicine and …

Recent evidence suggests a role for sigma (σ) binding sites in maintenance of cell growth
and/or proliferation. The present study examines, for the first time, the effect of σ binding site …

Taxol, characterized by increased activity in baseline lesions and the appearance of new
lesions, followed by improvement on follow-up scans. Evidence of clinical response (> 50 …